There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD – Research Report), Keros Therapeutics (KROS – Research Report) and Merus (MRUS – Research Report) with bullish sentiments.
Revolution Medicines (RVMD)
In a report issued on May 8, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines, with a price target of $48.00. The company’s shares closed last Thursday at $37.45, close to its 52-week high of $40.21.
According to TipRanks.com, Chang has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $43.90 average price target, an 11.8% upside from current levels. In a report released yesterday, Wedbush also initiated coverage with a Buy rating on the stock with a $46.00 price target.
See the top stocks recommended by analysts >>
Keros Therapeutics (KROS)
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Keros Therapeutics on May 8 and set a price target of $85.00. The company’s shares closed last Thursday at $57.60.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Keros Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $89.29, implying a 49.6% upside from current levels. In a report issued on May 8, Wells Fargo also maintained a Buy rating on the stock with a $88.00 price target.
Merus (MRUS)
Leerink Partners analyst Andrew Berens reiterated a Buy rating on Merus on May 8 and set a price target of $65.00. The company’s shares closed last Thursday at $45.12.
According to TipRanks.com, Berens is a 2-star analyst with an average return of
Merus has an analyst consensus of Strong Buy, with a price target consensus of $61.33, implying a 30.2% upside from current levels. In a report issued on May 8, Canaccord Genuity also maintained a Buy rating on the stock with a $54.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RVMD:
- Revolution Medicines files to sell 2.19M shares of common stock
- Revolution Medicines reports Q1 EPS (70c), consensus (75c)
- Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
- Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
- Revolution Medicines price target raised to $45 from $43 at Oppenheimer
